Breast cancer study: does ultra-high HER2 predict treatment success?
NCT ID NCT07376174
First seen Feb 01, 2026 · Last updated May 09, 2026 · Updated 14 times
Summary
This study looks at 300 people with HER2-positive breast cancer that hasn't spread. Researchers want to see if those with very high HER2 levels respond differently to a combination of two targeted drugs (trastuzumab and pertuzumab). The goal is to understand if HER2 levels can predict how long patients stay cancer-free after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Medical Oncology
RECRUITINGJinan, Shandong, China
Conditions
Explore the condition pages connected to this study.